Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Non-Insulin Therapies for Diabetes Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Alpha-glucosidase Inhibitors
      • 1.3.3 Amylin Agonists
      • 1.3.4 Biguanides
      • 1.3.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
      • 1.3.6 Glinides / Meglitinides
      • 1.3.7 GLP-1 Analogs / GLP-1 Agonists
      • 1.3.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
      • 1.3.9 Sulfonylureas
      • 1.3.10 Thiazolidinediones
      • 1.3.11 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global Non-Insulin Therapies for Diabetes Market Share by Application (2019-2025)
      • 1.4.2 Hospital Pharmacy
      • 1.4.3 Retail Pharmacies
      • 1.4.4 Online Pharmacy
      • 1.4.5 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Non-Insulin Therapies for Diabetes Market Size
      • 2.1.1 Global Non-Insulin Therapies for Diabetes Revenue 2014-2025
      • 2.1.2 Global Non-Insulin Therapies for Diabetes Sales 2014-2025
    • 2.2 Non-Insulin Therapies for Diabetes Growth Rate by Regions
      • 2.2.1 Global Non-Insulin Therapies for Diabetes Sales by Regions 2014-2019
      • 2.2.2 Global Non-Insulin Therapies for Diabetes Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Non-Insulin Therapies for Diabetes Sales by Manufacturers
      • 3.1.1 Non-Insulin Therapies for Diabetes Sales by Manufacturers 2014-2019
      • 3.1.2 Non-Insulin Therapies for Diabetes Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Non-Insulin Therapies for Diabetes Revenue by Manufacturers (2014-2019)
      • 3.2.2 Non-Insulin Therapies for Diabetes Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio (CR5 and HHI)
    • 3.3 Non-Insulin Therapies for Diabetes Price by Manufacturers
    • 3.4 Key Manufacturers Non-Insulin Therapies for Diabetes Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Non-Insulin Therapies for Diabetes Market
    • 3.6 Key Manufacturers Non-Insulin Therapies for Diabetes Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Alpha-glucosidase Inhibitors Sales and Revenue (2014-2019)
      • 4.1.2 Amylin Agonists Sales and Revenue (2014-2019)
      • 4.1.3 Biguanides Sales and Revenue (2014-2019)
      • 4.1.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors Sales and Revenue (2014-2019)
      • 4.1.5 Glinides / Meglitinides Sales and Revenue (2014-2019)
      • 4.1.6 GLP-1 Analogs / GLP-1 Agonists Sales and Revenue (2014-2019)
      • 4.1.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Sales and Revenue (2014-2019)
      • 4.1.8 Sulfonylureas Sales and Revenue (2014-2019)
      • 4.1.9 Thiazolidinediones Sales and Revenue (2014-2019)
      • 4.1.10 Others Sales and Revenue (2014-2019)
    • 4.2 Global Non-Insulin Therapies for Diabetes Sales Market Share by Type
    • 4.3 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type
    • 4.4 Non-Insulin Therapies for Diabetes Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Non-Insulin Therapies for Diabetes Sales by Application

    6 United States

    • 6.1 United States Non-Insulin Therapies for Diabetes Breakdown Data by Company
    • 6.2 United States Non-Insulin Therapies for Diabetes Breakdown Data by Type
    • 6.3 United States Non-Insulin Therapies for Diabetes Breakdown Data by Application

    7 European Union

    • 7.1 European Union Non-Insulin Therapies for Diabetes Breakdown Data by Company
    • 7.2 European Union Non-Insulin Therapies for Diabetes Breakdown Data by Type
    • 7.3 European Union Non-Insulin Therapies for Diabetes Breakdown Data by Application

    8 China

    • 8.1 China Non-Insulin Therapies for Diabetes Breakdown Data by Company
    • 8.2 China Non-Insulin Therapies for Diabetes Breakdown Data by Type
    • 8.3 China Non-Insulin Therapies for Diabetes Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Non-Insulin Therapies for Diabetes Breakdown Data by Company
    • 9.2 Rest of World Non-Insulin Therapies for Diabetes Breakdown Data by Type
    • 9.3 Rest of World Non-Insulin Therapies for Diabetes Breakdown Data by Application
    • 9.4 Rest of World Non-Insulin Therapies for Diabetes Breakdown Data by Countries
      • 9.4.1 Rest of World Non-Insulin Therapies for Diabetes Sales by Countries
      • 9.4.2 Rest of World Non-Insulin Therapies for Diabetes Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 GSK
      • 10.1.1 GSK Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Non-Insulin Therapies for Diabetes
      • 10.1.4 Non-Insulin Therapies for Diabetes Product Introduction
      • 10.1.5 GSK Recent Development
    • 10.2 Eli Lilly
      • 10.2.1 Eli Lilly Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Non-Insulin Therapies for Diabetes
      • 10.2.4 Non-Insulin Therapies for Diabetes Product Introduction
      • 10.2.5 Eli Lilly Recent Development
    • 10.3 Sumitomo Dainippon Pharma
      • 10.3.1 Sumitomo Dainippon Pharma Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Non-Insulin Therapies for Diabetes
      • 10.3.4 Non-Insulin Therapies for Diabetes Product Introduction
      • 10.3.5 Sumitomo Dainippon Pharma Recent Development
    • 10.4 Intarcia Therapeutics
      • 10.4.1 Intarcia Therapeutics Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Non-Insulin Therapies for Diabetes
      • 10.4.4 Non-Insulin Therapies for Diabetes Product Introduction
      • 10.4.5 Intarcia Therapeutics Recent Development
    • 10.5 Servier
      • 10.5.1 Servier Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Non-Insulin Therapies for Diabetes
      • 10.5.4 Non-Insulin Therapies for Diabetes Product Introduction
      • 10.5.5 Servier Recent Development
    • 10.6 Jiangsu Hansoh Pharmaceutical
      • 10.6.1 Jiangsu Hansoh Pharmaceutical Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Non-Insulin Therapies for Diabetes
      • 10.6.4 Non-Insulin Therapies for Diabetes Product Introduction
      • 10.6.5 Jiangsu Hansoh Pharmaceutical Recent Development
    • 10.7 Novo Nordisk
      • 10.7.1 Novo Nordisk Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Non-Insulin Therapies for Diabetes
      • 10.7.4 Non-Insulin Therapies for Diabetes Product Introduction
      • 10.7.5 Novo Nordisk Recent Development
    • 10.8 Emisphere
      • 10.8.1 Emisphere Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Non-Insulin Therapies for Diabetes
      • 10.8.4 Non-Insulin Therapies for Diabetes Product Introduction
      • 10.8.5 Emisphere Recent Development
    • 10.9 Uni-Bio Science Group
      • 10.9.1 Uni-Bio Science Group Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Non-Insulin Therapies for Diabetes
      • 10.9.4 Non-Insulin Therapies for Diabetes Product Introduction
      • 10.9.5 Uni-Bio Science Group Recent Development
    • 10.10 Takeda
      • 10.10.1 Takeda Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Non-Insulin Therapies for Diabetes
      • 10.10.4 Non-Insulin Therapies for Diabetes Product Introduction
      • 10.10.5 Takeda Recent Development
    • 10.11 3SBio
    • 10.12 Merck
    • 10.13 Dong-A Pharmaceutical
    • 10.14 Luye Pharma Group
    • 10.15 Eurofarma
    • 10.16 Geropharm
    • 10.17 Alkem Labs
    • 10.18 SatRx
    • 10.19 Pfizer
    • 10.20 Jiangsu Hengrui Medicine

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Non-Insulin Therapies for Diabetes Sales Channels
      • 11.2.2 Non-Insulin Therapies for Diabetes Distributors
    • 11.3 Non-Insulin Therapies for Diabetes Customers

    12 Market Forecast

    • 12.1 Global Non-Insulin Therapies for Diabetes Sales and Revenue Forecast 2019-2025
    • 12.2 Global Non-Insulin Therapies for Diabetes Sales Forecast by Type
    • 12.3 Global Non-Insulin Therapies for Diabetes Sales Forecast by Application
    • 12.4 Non-Insulin Therapies for Diabetes Forecast by Regions
      • 12.4.1 Global Non-Insulin Therapies for Diabetes Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Non-Insulin Therapies for Diabetes Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Non-Insulin Therapies for Diabetes is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Non-Insulin Therapies for Diabetes.

      This report studies the global market size of Non-Insulin Therapies for Diabetes, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Non-Insulin Therapies for Diabetes sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      GSK
      Eli Lilly
      Sumitomo Dainippon Pharma
      Intarcia Therapeutics
      Servier
      Jiangsu Hansoh Pharmaceutical
      Novo Nordisk
      Emisphere
      Uni-Bio Science Group
      Takeda
      3SBio
      Merck
      Dong-A Pharmaceutical
      Luye Pharma Group
      Eurofarma
      Geropharm
      Alkem Labs
      SatRx
      Pfizer
      Jiangsu Hengrui Medicine

      Market Segment by Product Type
      Alpha-glucosidase Inhibitors
      Amylin Agonists
      Biguanides
      Dipeptidyl Peptidase-4 (DPP4) Inhibitors
      Glinides / Meglitinides
      GLP-1 Analogs / GLP-1 Agonists
      Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
      Sulfonylureas
      Thiazolidinediones
      Others

      Market Segment by Application
      Hospital Pharmacy
      Retail Pharmacies
      Online Pharmacy
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Non-Insulin Therapies for Diabetes status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Non-Insulin Therapies for Diabetes manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Non-Insulin Therapies for Diabetes are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now